EPEleni Papakonstantinou

Eleni Papakonstantinou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eleni Papakonstantinou has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Resistance Training Improves Respiratory Muscle Strength and Immune Response in Older Adults: A Randomized Clinical Trial

    by Naiara Nadia Moreira-Silva, Meiry Souza Moura-Maia, Anamei Silva-Reis, Katielle Rodrigues Silva-Cardoso, Elano Silva-Sousa, Matheus Carrijo-Nascimento, Gustavo Paixão-Santos, Raianne Veiga-Celestino, Rosa Helena Ramos Paula-Vieira, Gaspar R. Chiappa, et al.

    Background: Aging is associated with sarcopenia, chronic low-grade inflammation, impaired functional capacity, and reduced respiratory muscle strength. Resistance training is recognized as an effective intervention to attenuate these age-related alterations; however, its effects on respiratory function and anti-aging biomarkers such as Klotho remain incompletely understood. Methods: In this randomized controlled trial, 60 community-dwelling older adults (60–75 years) were randomly allocated to a control group (n = 30) or a resistance training group (n = 30). Participants in the intervention group completed a supervised 12-week resistance training program (three sessions/week). Assessments performed before and after the intervention included anthropometry, body composition, respiratory muscle strength (maximal inspiratory and expiratory pressures), handgrip strength, 1 min sit-to-stand test, oxygen saturation, plasma levels of IL-6, IL-10, TNF-α, Klotho, and hematological parameters. Results: The resistance training group presented significantly increased maximal inspiratory and expiratory pressures, handgrip strength, and 1 min sit-to-stand performance while attenuating exercise-induced oxygen desaturation. The intervention also reduced plasma IL-6 concentrations and markedly increased circulating IL-10 and Klotho levels, indicating a favorable anti-inflammatory and anti-aging response. No significant changes were observed in systemic hematological parameters, whereas anthropometric adaptations were modest. Conclusions: Twelve weeks of resistance training significantly improved respiratory muscle strength and systemic inflammatory status in older adults. The concomitant increase in circulating Klotho suggests that resistance training may promote biological mechanisms associated with healthy aging, supporting its implementation as a non-pharmacological strategy to preserve functional independence and respiratory health in the elderly.

  • Open Access

    Cytomegalovirus in Bronchoalveolar Lavage Fluid: A Predictor of Outcome in Immunocompromised Patients

    by Theodora Zouvani, Meropi Karakioulaki, Kathleen Jahn, Sebastian Fähndrich, Björn C. Frye, Leticia Grize, Eleni Papakonstantinou, Hartmut Hengel, Karoline Leuzinger, Hans H. Hirsch, et al.

    Cytomegalovirus (CMV) is a prevalent herpesvirus that remains typically asymptomatic in immunocompetent individuals but can cause severe, potentially life‐threatening disease in immunocompromised patients. This study assessed the impact of CMV‐associated lower respiratory tract infections (LRTIs), diagnosed by polymerase chain reaction (PCR) testing of bronchoalveolar lavage fluid (BALF), focusing on coinfections and clinical outcomes. Between 2009 and 2017, a total of 2666 visits involving 1301 immunocompromised patients with suspected LRTI who underwent diagnostic bronchoalveolar lavage (BAL) were analyzed. The primary outcomes included CMV detection in BAL and resulting treatment modifications. Among these, 235 BALFs from 157 patients tested positive for CMV. Among these CMV‐positive cases, immunosuppression was classified as hematological conditions ( n = 88), solid organ transplantation ( n = 70), or other causes of immunosuppression ( n = 77). Overall, 59 cases exhibited isolated CMV infection, which was associated with a higher percentage of macrophages in BALF, compared to cases with CMV and coinfection [75.5%, 95% confidence interval (CI): 44.0–85.0 vs. 37.5%, 95% CI: 11.5%–67.0%, p = 0.008]. A total of 176 cases demonstrated CMV and coinfection, which were associated with neutrophilia in BALF (49.5%, 95% CI: 15.5–82.5; vs. CMV‐monoinfection: 7.5%, 95% CI:2–36, p = 0.002). BAL findings prompted treatment modifications in 61.7% ( n = 145) of all CMV‐positive cases. The 30‐day mortality rate was 13.6%, with a significantly elevated hazard ratio for those with CMV‐positive BAL diagnosis (unadjusted HR 2.85, 95% CI: 1.86–4.36). Cases with a CMV infection exhibited a significantly higher probability of requiring hospitalization compared to CMV‐negative cases, (OR 1.39, 95% CI: 1.03–1.87, p = 0.030). Immunocompromised patients have an increased risk of CMV infection, and the presence of CMV does not exclude a coinfection with other respiratory viruses, bacteria, or fungi. CMV detection in BALF was associated with higher hospitalization rates and mortality. Preventive and preemptive antiviral strategies are crucial, especially given the adverse impact of coinfections.

  • Open Access

    SUMF1 Common Variant rs793391 Is Associated with Response to Inhaled Corticosteroids in Patients with COPD

    by Charikleia Ntenti, Eleni Papakonstantinou, Leticia Grize, Maria Pascarella, Björn C. Frye, Sebastian Fähndrich, Despoina Ioannidou, Spasenija Savic Prince, Antonis Goulas, Daiana Stolz

    This study investigated whether specific sulfatase modifying factor-1 (SUMF1) SNPs—previously linked to lung function—are associated with COPD progression and response to inhaled corticosteroid (ICS) treatment, specifically budesonide, given that SUMF1 expression is altered in COPD and its variants linked to increased disease risk. A subgroup of 165 COPD patients from the HISTORIC study were genotyped for two common SUMF1 SNPs, rs11915920 and rs793391. Patients first underwent a six-week run-in phase with open-label triple inhaled therapy (LAMA/LABA/ICS), then were randomized to receive either LAMA/LABA/placebo or LAMA/LABA/ICS for 12 months. Associations between SNPs, baseline characteristics, and response to ICS—based on FEV1 change over 12 months—were evaluated. Heterozygotes (TG) for the rs793391 polymorphism treated with LAMA/LABA/ICS showed a significant and clinically meaningful FEV1 improvement compared to the placebo group. This was supported by improved patient-reported outcomes, with lower SGRQ and CAT scores and a clinically relevant increase in General Health Questionnaire scores. These findings suggest that rs793391 may be linked to both COPD progression and ICS response and could contribute to more personalized treatment strategies in COPD.


  • Open Access

    WISP1 and Macrophage Migration Inhibitory Factor in Respiratory Inflammation: Novel Insights and Therapeutic Potentials for Asthma and COPD

    by Maria-Elpida Christopoulou, Alexios J. Aletras, Eleni Papakonstantinou, Daiana Stolz, Spyros S. Skandalis

    Recent advancements highlight the intricate interplay between the extracellular matrix (ECM) and immune responses, notably in respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). The ECM, a dynamic structural framework within tissues, orches-trates a plethora of cellular processes, including immune cell behavior and tissue repair mecha-nisms. WNT1-inducible-signaling pathway protein 1 (WISP1), a key ECM regulator, controls immune cell behavior, cytokine production, and tissue repair by modulating integrins, PI3K, Akt, β-catenin, and mTOR signaling pathways. WISP1 also induces macrophage migration inhibitory factor (MIF) expression via Src kinases and epidermal growth factor receptor (EGFR) activation. MIF, through its wide range of activities, enhances inflammation and tissue restructuring. Rec-ognized for its versatile roles in regulating the immune system, MIF interacts with multiple immune components, such as the NLRP3 inflammasome, thereby sustaining inflammatory pro-cesses. The WISP1–MIF axis potentially unveils complex molecular mechanisms governing im-mune responses and inflammation. Understanding the intricate roles of WISP1 and MIF in the pathogenesis of chronic respiratory diseases such as asthma and COPD could lead to the identi-fication of novel targets for therapeutic intervention to alleviate disease severity and enhance patient outcomes.


  • Open Access

    The Genetics behind Sulfation: Impact on Airway Remodeling

    by Charikleia Ntenti, Eleni Papakonstantinou, Liana Fidani, Daiana Stolz, Antonis Goulas

    In COPD, chronic inflammation and exposure to irritants, such as cigarette smoke, lead to the thickening of bronchial walls. This results from increased deposition of collagen and other extracellular matrix components, contributing to the narrowing of airways. Nevertheless, it is widely recognized that COPD is an inflammatory disorder marked by partially reversible airflow limitation wherein genetic factors interact with the environment. In recent years, numerous investigations have substantiated the correlation between gene polymorphisms and COPD. SUMF1 has been implicated in diverse cellular processes, including lysosomal function and extracellular matrix maintenance, both of which play pivotal roles in respiratory health. The genetic variations in SUMF1 could lead to an imbalanced sulfation in the extracellular matrix of lung tissue, potentially playing a role in the onset of COPD. Recent studies have uncovered a potential link between dysregulation of SUMF1 and COPD progression, shedding light on its involvement in the abnormal sulfatase activity observed in COPD patients. Through a comprehensive review of current literature and experimental findings, this article aims to contribute to the growing body of knowledge surrounding the genetic intricacies concerning sulfation of airway remodeling and possible pharmacological applications in COPD and asthma management.


  • Airway smooth muscle area to predict steroid responsiveness in COPD patients receiving triple therapy (HISTORIC): a randomised, placebo-controlled, double-blind, investigator-initiated trial

    by Daiana Stolz, Eleni Papakonstantinou, Maria Pascarella, Kathleen Jahn, Aline Siebeneichler, Andrei M. Darie, Matthias J. Herrmann, Werner Strobel, Anna Salina, Leticia Grize, et al.

    Background: Although inhaled corticosteroids (ICS) are highly effective in asthma, they provide significant, but modest, clinical benefit in COPD. Here, we tested the hypothesis that high bronchial airway smooth muscle cell (ASMC) area in COPD is associated with ICS responsiveness.Methods: In this investigator-initiated and -driven, double-blind, randomised, placebo-controlled trial (HISTORIC), 190 COPD patients, Global Initiative for Chronic Obstructive Lung Disease stage B–D, underwent bronchoscopy with endobronchial biopsy. Patients were divided into groups A and B, with high ASMC area (HASMC: >20% of the bronchial tissue area) and low ASMC area (LASMC: ≤20% of the bronchial tissue area), respectively, and followed a run-in period of 6 weeks on open-label triple inhaled therapy with aclidinium (ACL)/formoterol (FOR)/budesonide (BUD) (400/12/400 μg twice daily). Subsequently, patients were randomised to receive either ACL/FOR/BUD or ACL/FOR/placebo and followed for 12 months. The primary end-point of the study was the difference in post-bronchodilator forced expiratory volume in 1 s (FEV1) over 12 months between patients with LASMC and HASMC receiving or not receiving ICS.Results: In patients with LASMC, ACL/FOR/BUD did not significantly improve FEV1over 12 months, as compared to ACL/FOR/placebo (p=0.675). However, in patients with HASMC, ACL/FOR/BUD significantly improved FEV1, as compared to ACL/FOR/placebo (p=0.020). Over 12 months, the difference of FEV1change between the ACL/FOR/BUD group and the ACL/FOR/placebo group was 50.6 mL·year−1within the group of patients with LASMC and 183.0 mL·year−1within the group of patients with HASMC.Conclusion: COPD patients with ΗASMC respond better to ICS than patients with LASMC, suggesting that this type of histological analysis may predict ICS responsiveness in COPD patients receiving triple therapy.


  • Open Access

    Ηeparan sulphate in infectious and non‐infectious exacerbations of COPD

    by Eleni Papakonstantinou, Maria‐Elpida Christopoulou, Meropi Karakioulaki, Leticia Grize, Michael Tamm, Daiana Stolz

    Background and Objective: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are associated with worsening health outcomes and effective treatment of each episode is essential. In this study, we aimed to investigate if plasma levels of heparan sulphate (HS) are associated with the aetiology of AECOPD.Methods: COPD patients (N = 1189), GOLD grade II–IV, from a discovery cohort (N = 638) and from a validation cohort (N = 551), were included in the study. HS and heparanase (HSPE‐1) were measured longitudinally in plasma at stable state, at AECOPD and at 4 weeks follow‐up.Results: Plasma HS was higher in patients with COPD as compared with non‐COPD controls and was significantly increased at AECOPD as compared to stable state (p < 0.001) in the discovery and in the validation cohorts. Four distinct exacerbation groups were classified based on aetiology (no‐infection/bacterial‐infection/viral‐infection/bacterial and viral coinfection) in the validation cohort. The fold‐increase of HS from stable state to AECOPD was associated with the aetiology of exacerbation and was higher in cases with bacterial and viral coinfections. HSPE‐1 was also significantly increased at AECOPD, however, there was no association of HSPE‐1 levels with the aetiology of these events. The probability of having an infection at AECOPD was raised as HS levels increased from stable state to AECOPD. This probability was higher for bacterial infections than viral infections.Conclusion: The results of our study indicate that circulating levels of HS are increased at AECOPD and this increase may be associated with the aetiology of these events.


  • Variability of fractional exhaled nitric oxide is associated with the risk and aetiology of COPD exacerbations

    by Desiree M. Schumann, Eleni Papakonstantinou, Konstantinos Kostikas, Leticia Grize, Michael Tamm, Daiana Stolz

    Background and Objective: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are heterogeneous in aetiology and accelerate disease progression. Here, we aimed to investigate the association of fractional exhaled nitric oxide (FeNO) and its variability with AECOPD of different aetiology.Methods: FeNO was determined in 2157 visits (1697 stable, 133 AECOPD and 327 follow‐up) of 421 COPD patients from the PREVENT study, an investigator‐initiated, longitudinal and interventional study, who were on daily treatment with inhaled corticosteroids/long‐acting β2‐agonists.Results: Longitudinal measurements of FeNO revealed an intra‐subject variability of FeNO that was significantly higher in exacerbators compared to non‐exacerbators (p < 0.001) and positively associated with the number of AECOPD. As FeNO variability increased, the probability of patients to remain AECOPD‐free decreased. In patients included in the highest FeNO variability quartile (≥15.0 ppb) the probability to remain free of AECOPD was only 35% as compared to 80% for patients included in the lowest FeNO variability quartile (0.50–4.39 ppb). The change of FeNO from the last stable visit to AECOPD was positively associated with the probability of viral infections and this association was stronger in current smokers than ex‐smokers. In contrast, the change in FeNO from the last stable visit to an AECOPD visit was inversely associated with the probability of bacterial infections in ex‐smokers but not in current smokers.Conclusion: FeNO variability was associated with the risk and aetiology of AECOPD differentially in current and ex‐smokers.


  • Effect of bronchial thermoplasty on histopathological parameters in distinct asthma endotypes/phenotypes

    by Eleni Papakonstantinou, Triantafyllia Koletsa, Liang Zhou, Lei Fang, Michael Roth, Meropi Karakioulaki, Spasenija Savic, Leticia Grize, Michael Tamm, Daiana Stolz

    Background: Bronchial thermoplasty (ΒΤ) regulates structural abnormalities involved in airway narrowing in asthma. Aim: Τo investigate the effect of ΒΤ on histopathological bronchial parameters in distinct asthma endotypes/phenotypes. Methods: Endobronchial biopsies (n=450) were collected from 30 patients with severe uncontrolled asthma before and after 3 sequential ΒΤs. Patients were classified based on blood eosinophils, atopy, allergy and smoke exposure. Tissue sections were assessed for histopathological parameters and expression of heat-shock proteins (HSPs). Proliferating cells were determined by Ki67-staining. Results: In all patients, BT improved asthma control (p<0.001), reduced airway smooth muscle (ASM) (p=0.014) and increased proliferative epithelial cells (p=0.014). After BT, ASM decreased predominantly in patients with T2 high asthma. Epithelial cell proliferation was increased after BT in patients with low blood eosinophils (p=0.016), patients with no allergy (p=0.028) and patients without smoke exposure (p=0.034). In all patients, BT increased the expression of HSP70 (p=0.002) and HSP90 (p=0.001) in epithelial cells and decreased the expression of HSP70 (p=0.009) and HSP90 (p=0.002) in subepithelial mesenchymal cells. The effect of BT on the expression of HSPs was distinctive across different asthma endotypes/phenotypes. Conclusions: BT is associated with decreased ASM, epithelial cell regeneration and increased expression of HSPs in the epithelium. Histopathological effects appear to be distinct in different endotypes/phenotypes indicating that the beneficial effects of BT are achieved by diverse molecular targets associated with asthma endotypes/phenotypes.

  • Open Access

    Serum Levels of Irisin and Omentin-1 in Breast Neoplasms and Their Association with Tumor Histology

    by Grigorios Panagiotou, Sofia Triantafyllidou, Basil C. Tarlatzis, Eleni Papakonstantinou

    Breast cancer is associated with obesity, possibly due to direct effects of adipokines and myokines, such as omentin-1 and irisin. In this study, we aimed to evaluate omentin-1 and irisin levels in women with benign and/or malignant breast neoplasms vs. healthy controls. Disease-free individuals (N = 56) and patients with histologically proven benign (N = 61) or malignant tumor (N = 96; subdivided into recently diagnosed/treatment-naïve (N = 72) and chemotherapy-treated (N = 24) subgroups) were enrolled in this study. Demographic, biochemical, and tumor histological characteristics were recorded. Body composition parameters were assessed using bioelectrical impedance. Serum irisin and omentin-1 levels were quantified with ELISA kits. In adjusted models, irisin levels were higher in both benign and malignant cases compared to controls but were comparable between neoplasms. Further adjustment for omentin-1 levels showed that age (odds ratio (OR) = 1.05, 95% confidence interval (95% CI) = (1.02, 1.08), ) and irisin levels (OR = 5.30, 95% CI = (1.24, 22.38), ) were independent predictors of the presence of malignancy. These molecules were associated with each other and with other anthropometric and demographic parameters. Irisin was associated with tumor histological characteristics including Ki67% levels, Elston-Ellis grading system, and estrogen receptors status. Omentin-1 was also associated with the Elston-Ellis grading system. In conclusion, serum irisin is increased in patients with both benign and malignant diseases of the breast. When combined with omentin-1, irisin concentration was associated with the presence of breast malignancy. This molecule’s role as a potential diagnostic and/or prognostic agent in breast malignancies warrants further investigation in larger prospective studies.